MediWound (MDWD) vs Niagen Bioscience (NAGE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
MediWound (MDWD) has outperformed Niagen Bioscience (NAGE) over the past year, losing 29.5% versus a loss of 64.2%. Over five years, MDWD leads with a -48.0% price change compared with -58.2% for NAGE. Niagen Bioscience is the larger company by market cap ($210.5 million vs $160.3 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MDWD | NAGE |
|---|---|---|
| Share price | $12.42 | $2.66 |
| Market cap | $160.35M | $210.48M |
| 1-day change | -3.35% | -2.21% |
| YTD return | -32.72% | -58.18% |
| 1-year return | -29.53% | -64.20% |
| 5-year return | -47.97% | -58.18% |
| P/E ratio (TTM) | — | 14.00 |
| Forward P/E | — | 26.60 |
| EPS (TTM) | $-2.17 | $0.19 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.03 | $7.95 |
| 52-week low | $12.42 | $2.61 |
| Distance from 52-week high | -37.99% | -66.54% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +146.94% | +354.14% |
| Average volume | 84.01K | 585.78K |
| Shares outstanding | 12.91M | 79.13M |
| Employees | 121 | 117 |
| Sector | Health Care | Health Care |
| Industry | Medicinal Chemicals and Botanical Products | Medicinal Chemicals and Botanical Products |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MDWD has outperformed NAGE by 34.7 percentage points over the past year.
About MediWound
MDWD stock →MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
Health Care · Medicinal Chemicals and Botanical Products · 121 employees
About Niagen Bioscience
NAGE stock →Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products.
Health Care · Medicinal Chemicals and Botanical Products · 117 employees
MDWD vs NAGE FAQ
Which is bigger, MediWound or Niagen Bioscience?
Niagen Bioscience (NAGE) is larger, with a market capitalization of $210.48M compared with $160.35M for MediWound (MDWD).
Which stock has performed better over the past year, MDWD or NAGE?
MDWD returned -29.53% over the past 12 months, compared with -64.20% for NAGE (price return, excluding dividends). Past performance does not predict future results.
Are MediWound and Niagen Bioscience in the same industry?
Yes. Both are classified in the Medicinal Chemicals and Botanical Products industry within the Health Care sector.